Company: CERO
Filing Date: 2025-05-07
Form Type: DEF 14A
Source: 0001213900-25-040263
Chunk: 140

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-07
Form: DEF 14A
Chunk 140
---
 be obligated to issue new certificates evidencing the shares of New Common Stock outstanding as a result of the reverse stock split unless and until the certificates evidencing the shares held by a holder prior to the reverse stock split are either delivered to the Corporation or its current transfer agent, or the holder notifies the Corporation or such transfer agent that such certificates have been lost, stolen or destroyed and executes an agreement satisfactory to the Corporation to indemnify the Corporation from any loss incurred by it in connection with such certificates. Holders who otherwise would be entitled to receive fractional share interests of New Common Stock upon the effectiveness of the reverse stock split shall be entitled to receive a whole share of New Common Stock in lieu of any fractional share created as a result of such reverse stock split.” THIRD: The stockholders of the Corporation have duly approved the foregoing amendment in accordance with the provisions of Section 211 and 242 of the General Corporation Law of the State of Delaware. IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be duly adopted and executed in its corporate name and on its behalf by its duly authorized officer as of the day of [•], 2025.

| CERO THERAPEUTICS HOLDINGS, INC. |     |                         |
| By:                              |     |                         |
| Name:                            |     | Chris Ehrlich           |
| Title:                           |     | Chief Executive Officer |

A-2 Appendix B THIRD AMENDMENT
TO THE
CERo THERAPEUTICS HOLDINGS, INC.
2024 EQUITY INCENTIVE PLAN This Amendment to the CERo Therapeutics Holdings, Inc. 2024 Equity Incentive Plan (“ Amendment ”) is hereby adopted by the Board of Directors (the “ Board ”) of CERo Therapeutics Holdings, Inc., a Delaware corporation (the “ Company ”). All capitalized terms not defined in this Amendment shall be defined as set forth in the Plan. WHEREAS, the Company maintains the CERo Therapeutics Holdings, Inc. 2024 Equity Incentive Plan (as previously amended, the “ Plan ”). WHEREAS, the Plan was originally adopted in 2024 with a reserve of 51,726 shares of common stock of the Company and a limit on the number of Incentive Stock Options that may be granted pursuant to the Plan of 50,993 Shares, and such amounts were increased by 20,000 shares each pursuant to the First Amendment to the Plan, dated April 30, 202